Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
DRUG: Savolitinib|DRUG: Placebo
PFS, Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), 17 months after the last patient enrolled
Safety and tolerability, Incidence and nature of treatment emergent adverse events (TEAE), the other safety variables including physical examination, vital signs and laboratory examinations, 17 months after the last patient enrolled|The objective response rate of the tumor (ORR), the incidence of confirmed complete response or partial response, 17 months after the last patient enrolled|The disease control rate (DCR), the incidence of complete response, partial response and stable disease, 17 months after the last patient enrolled|Duration of Response (DoR), the duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded, 17 months after the last patient enrolled|Overall survival (OS), the time from the date of randomization to the date of death (all causes), 17 months after the last patient enrolled|Time to Response (TTR), the period from the date of randomization to the date when the criteria for complete response or partial response was first measured (first record shall prevail)., 17 months after the last patient enrolled|PFS, Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), 17 months after the last patient enrolled|Development of diagnostic technology, The residual samples may be used for development of MET Companion Diagnostics (CDx), 17 months after the last patient enrolled
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib Combined with Osimertinib versus Placebo Combined with Osimertinib as the First-line Therapy for Patients with EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer